Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
50 hedge funds and large institutions have $4.23M invested in Zynerba Pharmaceuticals, Inc in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 14 closing their positions.
640% more call options, than puts
Call options by funds: $37K | Put options by funds: $5K
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
19% less funds holding
Funds holding: 62 → 50 (-12)
47% less capital invested
Capital invested by funds: $7.97M → $4.23M (-$3.74M)
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
+$12.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9.6K |
| 3 |
Morgan Stanley
New York
|
+$8.01K |
| 4 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$7.33K |
| 5 |
BWP
Bernardo Wealth Planning
Harleysville,
Pennsylvania
|
+$5.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$660K |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$474K |
| 3 |
D.E. Shaw & Co
New York
|
-$236K |
| 4 |
Renaissance Technologies
New York
|
-$171K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$96K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GSC
51
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$19K | -25,445 | Closed |
|
52
Verition Fund Management
Greenwich,
Connecticut
| – | -$15K | -20,078 | Closed |
|
53
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$14K | -18,200 | Closed |
|
|
PWA
54
PCG Wealth Advisors
Overland Park,
Kansas
| – | -$12K | -15,200 | Closed |
|
|
VF
55
Virtu Financial
New York
| – | -$11K | -14,812 | Closed |
|
56
LPL Financial
San Diego,
California
| – | -$9K | -12,563 | Closed |
|
57
Goldman Sachs
New York
| – | -$8K | -11,344 | Closed |
|
|
AAP
58
Arax Advisory Partners
Denver,
Colorado
| – | -$5K | -6,648 | Closed |
|
59
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.31K | -2,068 | -91% |
|
60
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$1K | -1,056 | Closed |
|
61
JP Morgan Chase
New York
| – | +$286 | +451 | +739% |
|
ZYNE Hedge Fund Activity: Q4 2022 in Review
50 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2022, worth a combined $4.23M — down 47% from $7.97M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ZYNE and 2 opened new positions — a net loss of 12 holders — while 16 trimmed existing stakes and 13 added.
The largest buyer was ExodusPoint Capital Management, adding an estimated $12.4K. The largest seller was Mirae Asset Global Investments, exiting entirely with an estimated $660K sold.
- 50 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2022, down from 62 in Q3 2022.
- Funds reported $4.23M of Zynerba Pharmaceuticals, Inc stock for Q4 2022, down 47% quarter-over-quarter.
- 2 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2022 and 14 closed out, a net change of -12 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q4 2022 was ExodusPoint Capital Management, an estimated $12.4K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q4 2022 was Mirae Asset Global Investments, an estimated $660K sold.
Based on aggregated 13F filings for Q4 2022.